During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Henlius successfully held its global oncologist reception, themed "Connecting Minds in Oncology." The event brought together leading oncologists, clinical researchers, and industry leaders from the U.S., Europe, and China to engage in in-depth dialogue on Henlius' R&D strategy, pipeline progress, and international collaborations.

Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, delivered the opening remarks. "As the global cancer burden continues to rise, we remain steadfast in our mission—rooted in China and reaching out to the world. With a patient-centric approach, we're driving forward innovation and accelerating international development," he said. "We aim to transform Henlius' innovations into accessible treatments for patients worldwide." He emphasized that this ASCO side event reflects Henlius' commitment to cross-border collaboration and its leadership in global oncology.

Following Dr. Zhu's remarks, Ping Cao, Chief Business Officer and Senior Vice President of Henlius, underlined the company's unwavering dedication to patient needs and elaborated on its strategic layout in both global market expansion and innovative drug development. She noted that Henlius would strive to bring more breakthrough therapies to patients across the globe through continuous technological innovation and international collaboration.

In the "Henlius Clinical Trial Pipeline" session, Dr. Ely Benaim, Henlius' US Chief Medical Officer, was joined by key investigators from China and the U.S., namely Dr. David Gandara, the leading principal investigators of the ASTRIDE study, Dr. Jaffer A. Ajani, the U.S. leading principal investigator of the HLX22-GC-301 study, as well as Prof. Jie Wang and her team and Dr. Fred Hirsch, the China and U.S. leading principal investigators for HLX43, to present key updates on Henlius' investigational therapies featured at ASCO 2025.

Dr. David Gandara, the principal leading investigators of the ASTRIDE study, Professor Emeritus and Co-Director of the Experimental Therapeutics Program at UC Davis Comprehensive Cancer Center (UCDCCC), shared his observations: "I have had the opportunity to work with many pharmaceutical companies as a consultant, including several from China. It is my observation that Henlius has the right mindset and organizational strategy to be successful in transitioning to the U.S. market. A high level of innovation and a rich pipeline of new agents places Henlius in the forefront. I was pleased to join them at their ASCO reception, give my perspective, and interact with leadership in helping to move their agenda forward."

Dr. Jaffer A. Ajani, Chair of the NCCN Gastric and Esophageal Cancers Panel and the U.S. leading principal investigator of the HLX22-GC-301 study, added: "I have had the pleasure to work on the phase 3 global protocol with Henlius on their very interesting HER2-targeting agent HLX22. During the refinement of this protocol—which is now approved also at U.T. MD Anderson Cancer Center—it has been delightful to interact with Henlius leadership. I look forward to help bring this trial to fruition and engage with Henlius' other assets."

Prof. Jie Wang, the leading PI of HLX43 from the Cancer Hospital of the Chinese Academy of Medical Sciences, along with Prof. Rui Wan, participated virtually. They shared insights into the clinical development plan and potential benefit trends of HLX43, adding a unique Chinese perspective to this global expert exchange. "HLX43 has demonstrated positive efficacy signals in its phase 1 clinical study, potentially becoming a versatile treatment option for multiple tumor types," said Prof. Wang. "We are pleased that this program has garnered attention at the ASCO and look forward to its continued global progress, enabling this innovative therapy to benefit more patients in the near future."

Dr. Fred Hirsch, former CEO of IASLC and Professor at the Icahn School of Medicine at Mount Sinai, also joined the discussion as the U.S. leading principal investigator for HLX43. He commented: "It was a great pleasure participating in Henlius' reception at ASCO in Chicago and to learn about a very impressive drug development portfolio, which gives promise to all the cancer patients."

In the final networking session, participants actively exchanged views on future partnership opportunities. The event not only reinforced Henlius' leadership in oncology R&D, but also served as a bridge for deeper international collaboration. Looking ahead, Henlius remains committed to accelerating its global clinical development and delivering innovative therapies to benefit more patients worldwide.